Financial Results for the Year 2025-26
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nectar Lifesciences reported a total comprehensive loss of Rs 2,928 crore for FY 2025-26 (vs loss of Rs 1,131 crore in prior year). The company completed a major restructuring: sold its entire pharma business (Active Pharmaceutical Ingredients and Formulation units) to Ceph Lifesciences via slump sale for Rs 12,539.85 crore, recognizing an exceptional gain of Rs 1,633.73 crore. It also sold menthol assets for Rs 200 crore and has a pending capsule business sale for Rs 199 crore. Continuing operations show near-zero revenue as the core business was sold. The company also incurred a significant loss of Rs 520.95 crore on mutual fund and equity investments due to market volatility. A share buyback of 3 crore shares at Rs 27 each (Rs 810 crore) was completed. The company is pivoting to real estate via a newly acquired subsidiary. Auditors issued an unmodified opinion.
The stock has essentially become a cash entity post-sale of its pharma business. While auditors flagged going concern as an emphasis area (Note 9), they gave an unmodified opinion citing adequate cash reserves and the company's solvent position. Shareholders face a transformed company with no operating revenue and a new real estate strategy.